Aandeel CMPX COMPASS THERAPEUTICS, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Compass Therapeutics, Inc.

Aandelen

CMPX

US20454B1044

Beurs gesloten - Nasdaq
Andere beurzen
 22:00:00 25-06-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
1,06 USD -4,50% Intraday-grafiek van Compass Therapeutics, Inc. -5,36% -32,05%
28/05 Compass Therapeutics, Inc. Kondigt wijzigingen aan in CEO CI
28/05 Compass Therapeutics, Inc. Kondigt wijzigingen in het management aan CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!
Gratis inschrijven
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
Compass Therapeutics : 2024 Proxy Supplemental
Compass Therapeutics Appoints Thomas Schuetz as CEO
Compass Therapeutics Announces CEO Transition
Compass Therapeutics, Inc. Announces CEO Changes
Compass Therapeutics, Inc. Announces Management Changes
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
Compass Therapeutics to Present Phase 1 Data for CTX-471, a Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology Annual Meeting 2024
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Top Premarket Gainers
Compass Therapeutics Gets FDA Fast-Track Designation for Biliary Tract Cancer Treatment
Compass Therapeutics Gets FDA Fast-Track for Cancer Treatment
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
Compass Therapeutics, Inc. Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
Compass Therapeutics : 2024 Proxy
Compass Therapeutics : Survey of CTX-009 Patient Selection Hypotheses Using Real World Biliary Tract Cancer Data
Compass Therapeutics Begins Dosing Patients in Trial of Potential Treatment for Multiple Cancers
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers CMPX
  4. Nieuws Compass Therapeutics, Inc.
  5. Andere talen